ライフサイエンスコーパス: myelomonocytic leukemia

1 MDS/MPN overlap syndrome (including chronic myelomonocytic leukemia).

2 n found in a subset of patients with chronic myelomonocytic leukemia.

3 ice that closely models juvenile and chronic myelomonocytic leukemia.

4 eloproliferative disorder resembling chronic myelomonocytic leukemia.

5 loid metaplasia, and, less commonly, chronic myelomonocytic leukemia.

6 es, including an increased risk for juvenile myelomonocytic leukemia.

7 viously described BTs with transformation to myelomonocytic leukemia.

8 ws efficacy in a nude mouse model of chronic myelomonocytic leukemia.

9 duct of the t(5;12) translocation in chronic myelomonocytic leukemia.

10 ight loss as initial manifestations of acute myelomonocytic leukemia.

11 d growth factor beta receptor causes chronic myelomonocytic leukemia.

12 in leukemic cells of a patient with chronic myelomonocytic leukemia.

13 ents with acute myeloid leukemia and chronic myelomonocytic leukemia.

14 ice had a disease similar to the human acute myelomonocytic leukemia.

15 r (PDGFbetaR) gene in a patient with chronic myelomonocytic leukemia.

16 5;12) translocation in patients with chronic myelomonocytic leukemia.

17 ome, acute myelogenous leukemia, and chronic myelomonocytic leukemia.

18 of mature pDCs has been described in chronic myelomonocytic leukemia.

19 ents with acute myeloid leukemia and chronic myelomonocytic leukemia.

20 tosis, including but not limited to, chronic myelomonocytic leukemia.

21 No patient with JXG developed chronic myelomonocytic leukemia.

22 ren with CBL syndrome and transient juvenile myelomonocytic leukemia.

23 elevant proportion of children with juvenile myelomonocytic leukemia.

24 yelodysplastic syndromes (MDSs), and chronic myelomonocytic leukemia.

25 d SRSF2 in 371 children with MDS or juvenile myelomonocytic leukemia.

26 A 3-year-old boy was treated for juvenile myelomonocytic leukemia.

27 econdary acute myeloid leukemia, and chronic myelomonocytic leukemia.

28 , genomic instability, and aggressive, fatal myelomonocytic leukemia.

29 s, myeloproliferative neoplasms, and chronic myelomonocytic leukemia.

30 bling the myeloproliferative form of chronic myelomonocytic leukemia.

31 true NK-cell tumors (n = 18), de novo acute myelomonocytic leukemias (1 of 14, 7%), or mature T-cell

32 ents suffering from MDS (n = 52) and chronic myelomonocytic leukemia-1 (n = 2).

33 ferative neoplasm (SM-MPN), 36 (29%) chronic myelomonocytic leukemia, 28 (23%) myelodysplastic syndro

34 ease: hematologic (MDS 84%, AML 14%, chronic myelomonocytic leukemia 8%), infectious (severe viral 70

35 clinical and molecular features with chronic myelomonocytic leukemia, a similar disease in adults.

36 liferative neoplasm (MPN), including chronic myelomonocytic leukemia, according to the International

37 ic syndrome, acute myeloid leukemia, chronic myelomonocytic leukemia, acute lymphoblastic leukemia, a

38 Juvenile myelomonocytic leukemia, acute myeloid leukemia (AML), a

39 survival (EFS), events being death and acute myelomonocytic leukemia (AML) transformation or progress

40 ner gene in the t(8;16) that occurs in acute myelomonocytic leukemia (AML-M4) de novo and rarely in t

41 n specific human cancers, including juvenile myelomonocytic leukemia, an aggressive myeloproliferativ

42 and SRSF2 mutations are frequent in chronic myelomonocytic leukemia and advanced forms of MDS.

43 sease, are frequent in patients with chronic myelomonocytic leukemia and are predictors of worse outc

44 tions are rare in pediatric MDS and juvenile myelomonocytic leukemia and are unlikely to operate as d

45 e-1 (FIP1L1)-PDGFRalpha, which cause chronic myelomonocytic leukemia and hypereosinophilic syndrome,

46 tantly, Bcl11a is expressed in human chronic myelomonocytic leukemia and juvenile myelomonocytic leuk

47 ey disease, with special emphasis on chronic myelomonocytic leukemia and lysozyme-induced nephropathy

48 closely related neoplasms (including chronic myelomonocytic leukemia and MDS-myeloproliferative neopl

49 Exposure of WEHI-3B D+ myelomonocytic leukemia and myeloid LGM-1 cells overexpr

50 tic AML, 7 (13%) of 52 patients with chronic myelomonocytic leukemia, and 1 (1%) of 68 patients with

51 h myelodysplastic syndrome, 118 with chronic myelomonocytic leukemia, and 126 with acute myeloid leuk

52 roblasts, TET2/SRSF2 comutation with chronic myelomonocytic leukemia, and activating CSF3R mutation w

53 All subtypes of myelodysplasia, chronic myelomonocytic leukemia, and acute myeloid leukemia with

54 leukemia, myelodysplastic syndromes, chronic myelomonocytic leukemia, and de novo and secondary acute

55 re common in acute myeloid leukemia, chronic myelomonocytic leukemia, and myelodysplastic syndrome.

56 r gene is frequently inactivated in juvenile myelomonocytic leukemia, and Nf1 mutant mice model this

57 ximately 75% incidence) and SRSF2 in chronic myelomonocytic leukemia ( approximately 28% incidence).

58 ted with marked thrombocytosis, and juvenile myelomonocytic leukemia, are clonal hematologic diseases

59 ptor (TEL-PDGFbetaR) is expressed in chronic myelomonocytic leukemias associated with t(5;12)(q33;p13

60 tive neoplasms (MDS/MPNs), including chronic myelomonocytic leukemia, atypical chronic myeloid leukem

61 We found missense mutations in 2 juvenile myelomonocytic leukemia cases and in 1 child with system

62 CMML progression or transformation to acute myelomonocytic leukemia (cause-specific HR, 0.62; 95% CI

63 uting to the pathogenesis of NS and juvenile myelomonocytic leukemia caused by PTPN11 gain-of-functio

64 MLL-AF6 leukemias as well as in ML2, a human myelomonocytic leukemia cell line bearing the t(6;11)(q2

65 cDNA encoding a CD34 homologue from a canine myelomonocytic leukemia cell line, ML2.

66 rminants of differentiation and apoptosis in myelomonocytic leukemia cells (U937) exposed to the nove

67 lcytosine (ara-C)-induced apoptosis in human myelomonocytic leukemia cells (U937).

68 rrows containing up to 50% lysis-susceptible myelomonocytic leukemia cells (U937).

69 at 50% of the cellular topo I in HL-60 human myelomonocytic leukemia cells became covalently bound to

70 Simultaneous exposure (24 h) of U937 myelomonocytic leukemia cells to 100 nM flavopiridol and

71 2 cells and apoptosis-proficient HL-60 acute myelomonocytic leukemia cells to etoposide were compared

72 n of TF mRNA and protein in SMC and in THP-1 myelomonocytic leukemia cells.

73 sented the spectrum of therapy-induced acute myelomonocytic leukemia/chronic myelomonocytic leukemia/

74 ed patients with higher-risk MDS and chronic myelomonocytic leukemia (CMML) 1:1:1 to azacitidine (75

75 Chronic myelomonocytic leukemia (CMML) and juvenile myelomonocyt

76 s of myeloid malignancies resembling chronic myelomonocytic leukemia (CMML) and myelodysplastic syndr

77 B fusion oncogene is associated with chronic myelomonocytic leukemia (CMML) and results in the expres

78 ations in 5% and 9% of patients with chronic myelomonocytic leukemia (CMML) and sAML, and also in CML

79 Myelodysplastic syndromes and chronic myelomonocytic leukemia (CMML) are characterized by muta

80 Myelodysplastic neoplasms (MDSs) and chronic myelomonocytic leukemia (CMML) are clonal disorders driv

81 d neoplasms, including 10% to 20% of chronic myelomonocytic leukemia (CMML) cases, and selectively di

82 myeloid leukemias (sAML) and 15% of chronic myelomonocytic leukemia (CMML) cases.

83 However, monocytoid precursors in chronic myelomonocytic leukemia (CMML) expressed VEGF in an inte

84 3;p13) translocation associated with chronic myelomonocytic leukemia (CMML) generates a TEL/PDGFbetaR

85 Drug development for chronic myelomonocytic leukemia (CMML) has failed to parallel th

86 Exome sequencing studies in chronic myelomonocytic leukemia (CMML) illustrate a mutational l

87 mouse model resemble those of human chronic myelomonocytic leukemia (CMML) in its transformation to

88 ckout converts Flt3-ITD-driven mouse chronic myelomonocytic leukemia (CMML) into AML with reduced sur

89 Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic

90 Chronic myelomonocytic leukemia (CMML) is a hematologic malignan

91 Chronic myelomonocytic leukemia (CMML) is a heterogeneous diseas

92 Chronic myelomonocytic leukemia (CMML) is a myelodysplastic synd

93 Chronic myelomonocytic leukemia (CMML) is a myelodysplastic/myel

94 Chronic myelomonocytic leukemia (CMML) is a severe myeloid malig

95 The natural course of chronic myelomonocytic leukemia (CMML) is highly variable but a

96 tients and from 12 of 20 (60%) adult chronic myelomonocytic leukemia (CMML) patients to 10(-9) mol/L

97 Here, we showed that chronic myelomonocytic leukemia (CMML) patients with ASXL1 mutat

98 myeloid leukemia (AML) patients, 32 chronic myelomonocytic leukemia (CMML) patients, and 96 healthy

99 us pathogenesis to those observed in chronic myelomonocytic leukemia (CMML) patients.

100 The diagnosis of chronic myelomonocytic leukemia (CMML) remains centered on morph

101 Human ASXL1 is mutated frequently in chronic myelomonocytic leukemia (CMML) so an ASXL/BAP1 complex m

102 ought to develop a survival model in chronic myelomonocytic leukemia (CMML) that is primarily based o

103 k myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) were randomized 1:1 to re

104 Adults with advanced MDS or chronic myelomonocytic leukemia (CMML) were randomized to 1 of 3

105 r (PDGFbetaR) gene in a patient with chronic myelomonocytic leukemia (CMML) with a t(5;7)(q33;q11.2)

106 omic DNA from 245 patients--119 with chronic myelomonocytic leukemia (CMML), 101 with MDS, 11 with hy

107 oring systems have been proposed for chronic myelomonocytic leukemia (CMML), a disease in which some

108 several chronic disorders, including chronic myelomonocytic leukemia (CMML), a hematological malignan

109 Chronic myelomonocytic leukemia (CMML), a myelodysplastic/myelop

110 for myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), acute myelogenous leukem

111 myeloproliferative neoplasms (MPNs), chronic myelomonocytic leukemia (CMML), and acute myeloid leukem

112 te myeloid leukemia (AML), CML, CLL, chronic myelomonocytic leukemia (CMML), and MDS.

113 (CLL), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), colorectal cancer, endom

114 e myelomonocytic leukemia (JMML) and chronic myelomonocytic leukemia (CMML), including identical soma

115 tion, with a fully penetrant, lethal chronic myelomonocytic leukemia (CMML), which was serially trans

116 ras G12D/+ bone marrow cells develop chronic myelomonocytic leukemia (CMML), while approximately 8% o

117 ng the myeloproliferative variant of chronic myelomonocytic leukemia (CMML), with a prolonged latency

118 NRAS rapidly and efficiently induced chronic myelomonocytic leukemia (CMML)- or acute myeloid leukemi

119 myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML).

120 clonal malignancy closely resembling chronic myelomonocytic leukemia (CMML).

121 cogenes in a subset of patients with chronic myelomonocytic leukemia (CMML).

122 been reported in some patients with chronic myelomonocytic leukemia (CMML).

123 ous leukemia (RAEB-T/AML), and 2 had chronic myelomonocytic leukemia (CMML).

124 (5;12) translocation associated with chronic myelomonocytic leukemia (CMML).

125 h myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML).

126 in particular ~40% of patients with chronic myelomonocytic leukemia (CMML).

127 d major changes to the definition of chronic myelomonocytic leukemia (CMML).

128 odeling associated with ASXL1(MT) in chronic myelomonocytic leukemia (CMML).

129 T2-WT) and mutant (TET2-MT) cases of chronic myelomonocytic leukemia (CMML).

130 y shown in the related human disease chronic myelomonocytic leukemia (CMML).

131 MPN that accurately models JMML and chronic myelomonocytic leukemia (CMML).

132 n of SRSF2 (Pro95) in 275 cases with chronic myelomonocytic leukemia (CMML).

133 iferative neoplasm, similar to human chronic myelomonocytic leukemia (CMML).

134 ent in acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML)/atypical chronic myelogen

135 yeloid malignancies, particularly in chronic myelomonocytic leukemia (CMML; 48%) and MDS/MPD-unclassi

136 lts with MDS/MPN subtypes, including chronic myelomonocytic leukemia (CMML; n = 119), atypical chroni

137 uch as chronic myelogenous (CML) and chronic myelomonocytic leukemias (CMML) are frequently induced b

138 derived colonies in 28 patients with chronic myelomonocytic leukemias (CMML), the most frequent MPN/M

139 c cell transplantation (allo-HCT) in chronic myelomonocytic leukemias (CMML), we assembled a retrospe

140 nd HY in advanced myeloproliferative chronic myelomonocytic leukemias (CMML).

141 astic syndrome (MDS) most similar to chronic myelomonocytic leukemia (CMMoL) and one other had dysery

142 with excess blasts (RAEB), and 1 had chronic myelomonocytic leukemia (CMMoL).

143 ergistic terminal differentiation of WEHI-3B myelomonocytic leukemia (D(+)) cells.

144 detection of shared origin of LCH and acute myelomonocytic leukemia driven by TET2-mutant CD34(+) ce

145 ectively analyzed 110 patients with juvenile myelomonocytic leukemia, given single-unit, unrelated do

146 zation and shares some features with chronic myelomonocytic leukemia in adults.

147 Chronic myelomonocytic leukemia is a prototypical myelodysplasti

148 Juvenile myelomonocytic leukemia is an aggressive and frequently

149 Juvenile myelomonocytic leukemia is an aggressive myeloproliferat

150 Chronic myelomonocytic leukemia, isolated 5q- syndrome, unclassi

151 venile chronic myelogenous leukemia/juvenile myelomonocytic leukemia (JCML/JMML).

152 y members are frequently mutated in juvenile myelomonocytic leukemia (JMML) and acute myeloid leukemi

153 features that overlap with those of juvenile myelomonocytic leukemia (JMML) and chronic myelomonocyti

154 tly occurring mutations in sporadic juvenile myelomonocytic leukemia (JMML) and JMML-like myeloprolif

155 acute lymphoblastic leukemia (ALL), juvenile myelomonocytic leukemia (JMML) and LEOPARD syndrome freq

156 hildren with NF1 are predisposed to juvenile myelomonocytic leukemia (JMML) and lethally irradiated m

157 matopoietic malignancies, including juvenile myelomonocytic leukemia (JMML) and T-cell lymphoblastic

158 ctive RAS signaling is prevalent in juvenile myelomonocytic leukemia (JMML) and the myeloproliferativ

159 myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) are myelodysplastic syndr

160 ) hypersensitivity is a hallmark of juvenile myelomonocytic leukemia (JMML) but has not been systemat

161 ndividuals with Noonan syndrome and juvenile myelomonocytic leukemia (JMML) have germline mutations i

162 Juvenile myelomonocytic leukemia (JMML) is a disease that occurs

163 Juvenile myelomonocytic leukemia (JMML) is a lethal disease of yo

164 Juvenile myelomonocytic leukemia (JMML) is a myeloproliferative d

165 Juvenile myelomonocytic leukemia (JMML) is a myeloproliferative d

166 Juvenile myelomonocytic leukemia (JMML) is a pediatric myelodyspl

167 Juvenile myelomonocytic leukemia (JMML) is a pediatric myeloproli

168 Juvenile myelomonocytic leukemia (JMML) is a poor-prognosis child

169 Juvenile myelomonocytic leukemia (JMML) is a rare and aggressive

170 Juvenile myelomonocytic leukemia (JMML) is a rare clonal myelopro

171 Juvenile myelomonocytic leukemia (JMML) is a rare heterogeneous h

172 Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferat

173 Juvenile myelomonocytic leukemia (JMML) is a rare pediatric myelo

174 Juvenile myelomonocytic leukemia (JMML) is a typically aggressive

175 Juvenile myelomonocytic leukemia (JMML) is a unique clonal hemato

176 Juvenile myelomonocytic leukemia (JMML) is a unique, aggressive h

177 Juvenile myelomonocytic leukemia (JMML) is an aggressive myelopro

178 Juvenile myelomonocytic leukemia (JMML) is an aggressive myelopro

179 Juvenile myelomonocytic leukemia (JMML) is an aggressive myelopro

180 Juvenile myelomonocytic leukemia (JMML) is an aggressive myelopro

181 Juvenile myelomonocytic leukemia (JMML) is an aggressive pediatri

182 Juvenile myelomonocytic leukemia (JMML) is an early childhood dis

183 Juvenile myelomonocytic leukemia (JMML) is characterized by hyper

184 Juvenile myelomonocytic leukemia (JMML) is characterized by myelo

185 Thirdly, using a juvenile myelomonocytic leukemia (JMML) patient-specific assay we

186 lear cells from five of seven (71%) juvenile myelomonocytic leukemia (JMML) patients and from 12 of 2

187 myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML) treated in a uniform fash

188 ting the molecular underpinnings of juvenile myelomonocytic leukemia (JMML) with the generation of in

189 own to underlie the pathogenesis of juvenile myelomonocytic leukemia (JMML), a fatal childhood diseas

190 s individuals to the development of juvenile myelomonocytic leukemia (JMML), a fatal myeloproliferati

191 PTPN11 (SHP-2) are associated with juvenile myelomonocytic leukemia (JMML), a myeloproliferative dis

192 sis type 1 (NF1) are predisposed to juvenile myelomonocytic leukemia (JMML), an aggressive myeloproli

193 dysplastic syndrome (A-MDS), 60 had juvenile myelomonocytic leukemia (JMML), and 6 infants with Down

194 al investigate the pathogenesis of juvenile myelomonocytic leukemia (JMML), demonstrating that mutan

195 te promyelocytic leukemia (APL) and juvenile myelomonocytic leukemia (JMML), we evaluated UAB8 isomer

196 ood acute leukemias, in addition to juvenile myelomonocytic leukemia (JMML), which is a myeloprolifer

197 L, and also in CML blast crisis and juvenile myelomonocytic leukemia (JMML).

198 associated with an elevated risk of juvenile myelomonocytic leukemia (JMML).

199 patients with de novo, nonsyndromic juvenile myelomonocytic leukemia (JMML).

200 of hematologic disorders, including juvenile myelomonocytic leukemia (JMML).

201 (ras), is frequently inactivated in juvenile myelomonocytic leukemia (JMML).

202 hildren with NF1 are predisposed to juvenile myelomonocytic leukemia (JMML).

203 myeloid malignancies, particularly juvenile myelomonocytic leukemia (JMML).

204 ferative disorders (MPD), including juvenile myelomonocytic leukemia (JMML).

205 nd the myeloproliferative variant of chronic myelomonocytic leukemia (JMML/MP-CMML).

206 g and is inactivated in a subset of juvenile myelomonocytic leukemias (JMMLs).

207 nd the myeloproliferative variant of chronic myelomonocytic leukemia (MP-CMML) in humans, and both ar

208 ons occur in children with sporadic juvenile myelomonocytic leukemia, myelodysplasic syndrome, B-cell

209 nduced acute myelomonocytic leukemia/chronic myelomonocytic leukemia/myelodysplastic/myeloproliferati

210 , some pediatric leukemias, such as juvenile myelomonocytic leukemia, myeloid leukemia of Down syndro

211 th chronic myeloid leukemia (n = 6), chronic myelomonocytic leukemia (n = 6), acute myeloid leukemia

212 antation model efficiently induces a chronic myelomonocytic leukemia- or acute myeloid leukemia-like

213 In 1 juvenile myelomonocytic leukemia patient, the SRSF2 mutation that

214 BCOR is also mutated in chronic myelomonocytic leukemia patients (7.4%) and BCORL1 in AM

215 n 161 of 1458 patients (11%); 26% of chronic myelomonocytic leukemia patients harbored 7q uniparental

216 s and for treatment of the subset of chronic myelomonocytic leukemia patients with a TEL-PDGFR fusion

217 Juvenile myelomonocytic leukemia patients without PTPN11 mutation

218 Proliferative chronic myelomonocytic leukemia (pCMML), an aggressive CMML subt

219 Decitabine's mechanism of action in chronic myelomonocytic leukemia remains incompletely understood.

220 acute myeloid leukemia) or acquired (chronic myelomonocytic leukemia) RUNX1 mutations.

221 chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia samples.

222 s SM-MPN, systemic mastocytosis with chronic myelomonocytic leukemia, SM-MDS, and systemic mastocytos

223 ures and outcomes of therapy-related chronic myelomonocytic leukemia (t-CMML) and compare with those

224 lomonocytic origin, and a diagnosis of acute myelomonocytic leukemia was rendered.

225 Patients with chronic myelomonocytic leukemia were first screened for JAK2 and

226 actory acute myelogenous leukemia or chronic myelomonocytic leukemia were treated with 10.36 to 37.0

227 ed in human leukemias, particularly juvenile myelomonocytic leukemia, which is characterized by hyper

228 mia [RA]/RA with ringed sideroblasts/chronic myelomonocytic leukemia with < 5% bone marrow blasts, 63

229 ronic myeloproliferative syndrome or chronic myelomonocytic leukemia with eosinophilia.